

# **Super-Curcumin Story**

**Chapter 1: Curcumin is excellent compound for various medicinal usages**

**Chapter 2: Discovery of Super-Curcumin analog**

**Chapter 3: Anti-tumor activities of Super-Curcumin analog**

**Chapter 4: Molecular targets of analogs**

**Chapter 5: Oncogenes & analogs**

**Chapter 6: Apoptosis & analogs**

**Chapter 7: Cancer stem cells & analogs**


**Chapter 8: Analogs lead drug discovery**

**Supplement: Super-Curcumin analog & Sleeping sickness (African trypanosomiasis)**




# Chapter 1: Curcumin is excellent compound for various medicinal usages

## Curcumin



IUPAC name; (1E,6E)-1,7-bis (4-hydroxy-3-methoxyphenyl) -1,6- heptadiene-3,5-dione

## Curcumin is a multi-targeted compound




Curcumin can stop the individual gears of wheels in cancer.




**Curcumin man**


# Why does curcumin have a multiplicity of targets?




# How can curcumin control multiple targets? – “Resilience”-



## Chapter 2: Discovery of Super-Curcumin analog




# Chapter 3: Anti-tumor activities of Super-Curcumin analog




Over 100 species of analogs were synthesized from one lead compound, and the anti-tumor activities against 16 types of cancer cell lines were examined.

Analogues can kill the cancer cells at concentrations 30 – 60 times lower than 5-FU, cisplatin, irinotecan.



## Analogues bearing strong anti-tumor activities




**They have a 84 times stronger activity than Curcumin.**



# Chapter 4: Molecular targets of analogs


Analogs have different mechanisms from approved cytotoxics.

This structure is important.



Stronger anti-tumor activities

No anti-tumor activities




# Chapter 5: Oncogenes & analog


**Analogs target oncogene products.**

**Malignant phenotypes**

- 1. Loss of growth control**
- 2. Resistance to apoptosis**
- 3. Immortality**
- 4. Angiogenesis**
- 5. Invasion**
- 6. Metasatasis**




**Her2 inhibitor**




**Myc inhibitor**

**Analogs can regulate overexpressed oncogene products such as ,,,,**

**c-Myc, KRAS, CyclinD1, ErbB2, β-catenin, COX-2,, (examined).**



**KRAS inhibitor**



**NF-κB inhibitor**



# Chapter 6: Apoptosis & analogs

**Analogs can induce apoptosis.**


## Malignant phenotypes

1. Loss of growth control
2. **Resistance to apoptosis**
3. Immortality
4. Angiogenesis
5. Invasion
6. Metasatasis




Analogs can induce apoptosis related proteins such as ,, ,, ,, ,, ,, ,, ,,  
**Caspases, PARP, TP53, XIAP, DR5,, (examined).**

**control      curcumin      GO-Y030**




**Apoptotic DLD-1 cells**


## Caspases induction



## P53 induction



## Death receptor induction



# Chapter 7: Cancer stem cells & analogs


## Analogs can kill cancer stem cells.

**Cancer stem cell is like a queen bee. She is resistant to chemotherapy.**


**sensitive** **resistant**




## Phosphorylation of STAT3 is characteristic to cancer stem cells.



**Analogs can bind phosphorylation site of STAT3, and inhibit STAT3 signaling.**




**Analogs can inhibit cancer stem cell growth *in vivo*.**




# Chapter 8: Potential against rare cancers

## Rare cancers - CTCL -


The incidence; < 1 / 100 000  
in the United States



### Growth-suppressive potentials – CTCL cell lines -





30 to 60 times higher than curcumin



Analogs have no HDAC inhibitory effects. Combination with SAHA?



# Animal models - CTCL -



**CTCL can be cured in animal model.**

## Anti-tumor effect (at sacrifice)


	Complete Regression	Regression	No change	Enlargement
Cont (n=8)	0 (0)	0 (0)	1 (12.5)	7 (87.5)
030 (n=10)	6 (60.0)	0 (0)	3 (30.0)	1 (10)
078 (n=11)	1 (9.1)	0 (0)	3 (27.3)	7 (63.6)

**P=0.001176**


**P=0.00565**

(Kruskal-Wallis)

# Rare cancers - Multiple myeloma -







## MTT Assay




72hr treatment

# Chapter 9: Anti-angiogenic potential of analogs








Angiogenesis inhibition (Xenopus Embryo)  
/GO-Y078 (20  $\mu\text{M}$ )





# Chapter 10: Radioprotection




## Chapter 11:


### 1. Improvement of solubility

**Curcumin is low bioavailable (insoluble in water, poor absorption).**

*C<sub>5</sub>-Curcuminoid-thiol adduct as prodrug (12 compounds)*





**Curcumin**  
 $GI_{50} = 16 \mu\text{M}$



**GO-Y030**  
 $GI_{50} = 0.3 \mu\text{M}$


**Low solubility**



**GO-Y140**  
 $GI_{50} = 3.3 \mu\text{M}$

**Solubility** ↑


GO-Y030



GO-Y140

30 mg compound  
in pH8 PBS buffer


## 2. Antibody-Drug Conjugate




## Chapter 12: Future Directions

### 1. An analog was detected in curry.

It is potent to suppress gastric cancer *in vivo*.



### 2. Analogs could induce anti-tumor immunity, like curcumin.



## Appendix (1): Patent Right

**We got US and Japan patents.**



(19) 日本国特許庁 (JP)	(12) 特許公報 (B2)	(11) 特許番号 特許第5050206号 (P5050206)
(45) 発行日 平成24年10月17日 (2012. 10. 17)	(24) 登録日 平成24年8月3日 (2012. 8. 3)	



(12) <b>United States Patent</b> Shibata et al.	(10) Patent No.: <b>US 8,178,727 B2</b>
	(45) Date of Patent: <b>May 15, 2012</b>



**Analog man**



## Appendix (2): Analog & Sleeping sickness (African trypanosomiasis)

Analogs may be effective for trypanosomiasis (sleeping sickness).

*In vitro* anti-trypanosomal activity against *Trypanosoma brucei brucei* GUTat 3.1 and cytotoxicity in MRC-5 cells of curcumin and GO-Y0xx compounds

Analog	Growth inhibition IC50 (µg/ml)		Safety Index
	Anti-trypanosomia activity	Cyto-toxicity	
Curcumin	0.66	3.32	5.0
GO-Y015	1.32	38.37	29.1
GO-Y023	0.53	13.19	24.9
GO-Y038	0.078	5.09	65.3
GO-Y050	0.33	13.62	41.3
GO-Y052	0.46	10.99	23.9
GO-Y056	0.21	5.33	25.4
GO-Y057	0.44	7.17	16.3
Suramin	1.58	>100	>63
Eflornithine	2.27	>100	>44



**Recruit Collaborators!!**